Blue Jet Health Peer Comparison
NSE: BLUEJET | BSE: 544009
₹569.80
₹-9.20
(-1.59%)
As on 04-Sep-2026 15:56IST
Market cap
₹10,773 Cr
Revenue (TTM)
₹886 Cr
P/E Ratio
45.9
P/B Ratio
4.8
Div. Yield
0.2 %
Edit
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
10,773 | 36,584 | 29,051 | 16,782 | 15,009 |
Revenue (₹ Cr) |
886 | 9,683 | 2,372 | 2,590 | 676 |
Net Profit (₹ Cr) |
234.91 | 1,018.97 | 497.77 | 603.02 | 183.60 |
Net Margin (%) |
24.44 | 10.47 | 20.72 | 22.63 | 26.06 |
RoE (%) |
17.96 | 21.30 | 28.49 | 19.61 | 22.72 |
Price to Earnings |
45.86 | 36.17 | 58.36 | 27.83 | 82.18 |
Price-To-Book |
4.81 | 6.99 | 14.37 | 4.82 | 16.25 |
Income Statement (₹ Cr)
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
947.32 | 9,203.54 | 2,022.99 | 2,551.83 | 642.26 |
|
Total Income
|
1,015.98 | 9,335.01 | 2,053.15 | 2,612.24 | 670.84 |
|
Total Expenditure
|
653.22 | 7,457.80 | 1,448.49 | 1,754.55 | 419.46 |
|
EBITDA
|
294.10 | 1,745.74 | 574.50 | 797.28 | 222.80 |
|
Depreciation
|
24.00 | 415.05 | 91.74 | 75.36 | 14.81 |
|
EBIT
|
270.10 | 1,330.70 | 482.76 | 721.93 | 207.99 |
|
Interest
|
6.24 | 143.67 | 23.95 | 5.37 | 8.50 |
|
Other Income
|
68.65 | 131.47 | 30.17 | 60.41 | 28.59 |
|
Exceptional Items
|
-- | -31.35 | 76.40 | -25.66 | -- |
|
Profit before Tax
|
332.51 | 1,287.14 | 488.98 | 751.31 | 228.07 |
|
Provision for Tax
|
84.70 | 345.87 | 124.98 | 186.83 | 53.79 |
|
Profit after Tax
|
247.82 | 941.27 | 364.00 | 564.48 | 174.28 |
Liabilities (₹ Cr)
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,359.91 | 4,950.03 | 1,874.47 | 3,332.13 | 883.34 |
|
Minority Interest
|
-- | 26.64 | -- | -- | 14.75 |
|
Non-Current Liabilities
|
350.27 | 584.19 | 345.47 | 142.73 | 74.33 |
|
Current Liabilities
|
276.66 | 3,912.24 | 710.20 | 682.24 | 201.96 |
|
Total Liabilities
|
1,986.84 | 9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 |
Assets (₹ Cr)
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
980.60 | 3,861.01 | 1,447.01 | 1,333.54 | 550.42 |
|
Current Assets
|
1,006.25 | 5,612.10 | 1,483.13 | 2,823.56 | 623.97 |
|
Total Assets
|
1,986.84 | 9,514.48 | 2,930.14 | 4,157.10 | 1,174.38 |
|
Total Debt*
|
0.00 | 1,204.08 | 196.61 | 0.00 | 148.29 |
|
Net Current Assets
|
729.59 | 1,699.86 | 772.93 | 2,141.33 | 422.00 |
|
Contingent Liabilities
|
0.68 | 258.92 | 13.18 | 4.82 | 0.10 |
Cashflow (₹ Cr)
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
334.15 | 943.55 | 346.68 | 565.41 | 69.55 |
|
Cash Flow from Investing Activities
|
-275.58 | -1,193.06 | -423.73 | -570.15 | -330.93 |
|
Cash from Financing Activities
|
-30.69 | 343.43 | 20.98 | -64.34 | 247.29 |
|
Net Cash Inflow / Outflow
|
27.88 | 93.92 | -56.08 | -69.08 | -14.09 |
Ratios
Profitability Ratios
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
27.18 | 25.25 | 27.50 | 24.61 | 28.50 |
|
ROE (%)
|
19.88 | 20.09 | 21.43 | 18.41 | 25.37 |
|
ROA (%)
|
13.58 | 10.70 | 14.25 | 14.27 | 18.43 |
|
EBIT Margin (%)
|
38.29 | 20.40 | 29.89 | 33.61 | 39.14 |
|
Net Margin (%)
|
24.39 | 10.08 | 17.73 | 21.61 | 25.98 |
|
Cash Profit Margin (%)
|
28.69 | 14.44 | 22.53 | 24.81 | 28.90 |
Growth Ratios
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-8.03 | 16.56 | 36.98 | 6.91 | 27.94 |
|
EBIT Growth (%)
|
-14.44 | 21.77 | 75.89 | 19.60 | 25.48 |
|
Net Profit Growth (%)
|
-18.80 | 33.05 | 39.94 | 16.24 | 25.63 |
|
EPS Growth (%)
|
-18.80 | 35.59 | 39.94 | 16.05 | 7.28 |
|
Book Value Growth (%)
|
20.02 | 11.36 | 22.95 | 18.43 | 79.97 |
Valuation Ratios
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
22.91 | 32.73 | 42.34 | 21.18 | 38.70 |
|
Price / Book Value
|
4.17 | 6.13 | 8.23 | 3.60 | 7.57 |
|
Dividend Yield (%)
|
0.37 | 0.23 | 0.28 | 0.51 | 0.25 |
|
EV/EBITDA
|
15.24 | 16.68 | 25.23 | 13.94 | 26.75 |
|
Market Cap (₹ Cr)
|
5,676.63 | 30,257.56 | 15,412.11 | 11,956.86 | 6,690.53 |
Solvency Ratios
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.24 | 0.10 | 0.00 | 0.17 |
|
Short term debt to equity ratio
|
-- | 0.16 | -- | -- | 0.12 |
|
Current Ratio
|
3.64 | 1.43 | 2.09 | 4.14 | 3.09 |
|
Quick Ratio
|
2.96 | 0.82 | 1.37 | 3.12 | 2.02 |
|
Interest Coverage
|
54.30 | 9.96 | 21.42 | 140.86 | 27.82 |
Operating Efficiency Ratios
| Blue Jet Health | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
35.79 | 27.84 | 26.76 | 42.05 | 35.43 |
|
Asset Turnover
|
0.52 | 1.07 | 0.79 | 0.65 | 0.69 |
|
Receivable days
|
132.65 | 88.68 | 77.32 | 144.58 | 115.16 |
|
Inventory Days
|
86.94 | 84.11 | 80.83 | 96.67 | 96.15 |
|
Payable days
|
61.13 | 176.65 | 125.94 | 135.45 | 106.08 |
|
Cash Conversion Cycle
|
158.47 | -3.86 | 32.22 | 105.80 | 105.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
